Schisandrin A restrains osteoclastogenesis by inhibiting reactive oxygen species and activating Nrf2 signalling
Cell Proliferation2020Vol. 53(10), pp. e12882–e12882
Citations Over TimeTop 10% of 2020 papers
Shuo Ni, Zhi Qian, Yuan Yin, Dejian Li, Zeyuan Zhong, Farnaz Ghorbani, Xu Zhang, Fangxue Zhang, Zhenhua Zhang, Zichen Liu, Baoqing Yu
Abstract
Our results showed the potential of anti-oxidant compound schisandrin A in the treatment of osteoporosis, highlighting Nrf2 as a novel promising target in osteoclast-related disease.
Related Papers
- → TNF‑α and RANKL promote osteoclastogenesis by upregulating RANK via the NF‑κB pathway(2018)144 cited
- → An inhibitory role for caspase‐3 at the late stage of RANKL‐induced osteoclast differentiation in RAW264 cells and mouse bone marrow macrophages(2014)4 cited
- → The effects of tumor necrosis factor-α on osteoclast formation depend on the haematopoietic precursors(2006)
- 64Cu-RGD and microPET/CT as an imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation(2009)
- → Inhibitory Effect of Agrocybe Chaxingu (Chaxines) on RANKL-Induced Osteoclast Differentiation in RAW246.7 Cells: Possible Prevention of Osteoporosis(2022)